The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Primary Biliary Cholangitis Market Between 2026 And 2030?
The market size for primary biliary cholangitis has shown substantial growth in recent years. It is anticipated to expand from $1.06 billion in 2025 to $1.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. This historical growth can be largely attributed to an improved understanding of autoimmune liver diseases, an increase in the availability of diagnostic testing, the expansion of specialty liver clinics, a rising clinical awareness of PBC symptoms, and the development of standard pharmacological treatments.
The market size for primary biliary cholangitis is anticipated to experience robust expansion over the next few years, projected to reach $1.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This growth during the forecast period is attributable to heightened investments in rare disease research, an increasing uptake of personalized medicine strategies, the expansion of advanced imaging diagnostic tools, a growing pipeline of targeted therapies, and a stronger focus on managing the disease in its early stages. Furthermore, significant trends expected in this period include a greater emphasis on targeted drug therapies, the rising adoption of sophisticated diagnostic imaging techniques, the increasing integration of biomarker-based disease monitoring, the broadening of personalized treatment approaches, and an enhanced focus on early disease detection.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp
Which Key Factors Are Driving The Primary Biliary Cholangitis Market Growth?
An increase in liver cancer is anticipated to boost the expansion of the primary biliary cholangitis market. Liver cancer, which originates in the liver’s cells, is a form of malignancy. Primary biliary cholangitis plays a crucial role in the context of liver cancer, as it significantly raises the likelihood of developing various cancers, including cholangiocarcinoma and hepatocellular carcinoma. The increasing occurrence of the disease and its potential complications further contribute to the expansion of the primary biliary cholangitis market. For example, in January 2024, the American Cancer Society, a prominent professional body in the U.S., forecasted about 41,630 new liver cancer diagnoses nationwide, comprising 28,000 cases among men and 13,630 among women. Additionally, approximately 29,840 individuals (19,120 men and 10,720 women) are anticipated to die from this illness. Consequently, the rising incidence of liver cancer is a key factor propelling the expansion of the primary biliary cholangitis market.
How Is Segmentation Applied In The Primary Biliary Cholangitis Market Segment Analysis?
The primary biliary cholangitis market covered in this report is segmented –
1) By Treatment Type: Drugs, Liver Transplantation
2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses
3) By End-Users: Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant
Which Trends Are Guiding The Direction Of The Primary Biliary Cholangitis Market?
Leading companies in the primary biliary cholangitis market are focusing on developing innovative and specialized treatments, such as orphan drugs that combine obeticholic acid (OCA) and bezafibrates to address primary biliary cholangitis (PBC), in order to secure market exclusivity. This specific combination of OCA and bezafibrate, with its orphan drug designation, is designed to present a more comprehensive and effective strategy for managing PBC treatment, potentially elevating the quality of life for individuals afflicted by this uncommon condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, was granted orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, for its potential use as a treatment for primary biliary cholangitis (PBC), which is a progressive liver disease. Furthermore, obeticholic acid (marketed as Ocaliva) is already approved for PBC in the US.
Who Are The Companies Participating In The Primary Biliary Cholangitis Market Environment?
Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals
Get The Full Primary Biliary Cholangitis Market Report:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Which Region Leads The Primary Biliary Cholangitis Market In Terms Of Market Share?
North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Primary Biliary Cholangitis Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company
Polyclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report
Diagnostic Specialty Antibodies Market Report
Next Generation Antibody Therapeutics Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model